IP Library Granted Patent US 6,933,149
Granted Patent B2
US 6,933,149 · App. 10/132,680 · Granted Aug 23, 2005

Culture system for mouse tracheal epithelial cells

Assignee: North Carolina State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,933,149
App. No.
10/132,680
Granted
Aug 23, 2005
Kind
B2
Abstract

Cultured mouse tracheal epithelial are grown in an air/liquid interface culture that allows them to develop differentiated characteristics (i.e., to develop into mucus cells or ciliated cells). This invention may be used for the growth of cells isolated from knockout and transgenic mice. The primary culture cells of the culture may be ciliated or non-ciliated differentiated cells.

Claims (18)

1. A method for producing a culture of differentiated, mouse airway epithelial cells comprising at least 5% mucus cells comprising:

obtaining tracheal epithelial cells from a mouse; and then

maintaining the cells at an air-liquid interface to produce a culture of mouse airway epithelial cells comprising at least 5% mucus cells, whereby the cells remain differentiated.

2. The method according to claim 1 , whereby the maintenance step comprises:

growing the tracheal epithelial cells on a solid support, wherein a first side of the support is in contact with a basolateral medium, and a second side of the support is in contact with an apical medium;

removing the apical medium to create the air-liquid interface; and

continuing to grow the epithelial cells at the air-liquid interface.

3. The method according to claim 2 , wherein the solid support is a semi-permeable membrane.

4. The method according to claim 2 , wherein the basolateral medium comprises serum.

5. The method according to claim 2 , wherein the basolateral medium comprises 5% to 10% serum.

6. The method according to claim 2 , wherein the basolateral medium comprises serum until the air-liquid interface is created.

7. The method according to claim 1 , wherein the mouse is a transgenic mouse.

8. The method according to claim 1 , wherein the mouse is a knockout mouse.

9. The method according to claim 1 , wherein the tracheal epithelial cells produce mucin.

10. The method according to claim 1 , wherein the culture further comprises ciliated cells.

11. The method according to claim 1 , wherein the culture further comprises goblet cells.

12. The method according to claim 1 , wherein the tracheal epithelial cells proliferate in response to an inflammatory mediator.

13. The method according to claim 12 , wherein said inflammatory mediator is IL-13.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jun 22, 2017
From: NORTH CAROLINA STATE UNIVERSITY RALEIGH
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 042781/0945 →
CONFIRMATORY LICENSE Recorded Jun 1, 2017
From: NORTH CAROLINA STATE UNIVERSITY RALEIGH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042645/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2002
From: MARTIN, LINDA D.; ADLER, KENNETH B.; MACCHIONE, MARIANGELA; AKLEY, NANCY K.; MCKANE, SHAUN A.
To: NORTH CAROLINA STATE UNIVERSITY
Reel/Frame 013152/0443 →
Continuity (2)
Provisional Application 6028763800 · Apr 30, 2001
Related Publication 20020197715A1 · Dec 26, 2002